Hinova Pharmaceuticals Inc
SSE:688302
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Hinova Pharmaceuticals Inc
Change in Working Capital
Hinova Pharmaceuticals Inc
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
Hinova Pharmaceuticals Inc
SSE:688302
|
Change in Working Capital
-¥186.8m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Change in Working Capital
-¥382.8m
|
CAGR 3-Years
15%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Change in Working Capital
-¥17.8B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-12%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Change in Working Capital
-¥6.6B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-8%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Change in Working Capital
-¥2.3B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-12%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Change in Working Capital
-¥1.5B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
Hinova Pharmaceuticals Inc
Glance View
Hinova Pharmaceuticals, Inc. engages in the research and development of pharmaceutical products. The company is headquartered in Chengdu, Sichuan and currently employs 160 full-time employees. The company went IPO on 2022-04-12. The firm focuses its research on the fields of tumor, metabolic diseases and other critical illnesses. The firm's research platforms include a deuterated drug development platform, a Proteolysis-targeting chimera (PROTAC) technology platform, a targeted drug discovery and validation platform, and a lead compound optimization screening platform. The firm has diversified product portfolios, which are in various clinical test phases, including HC-1119 for prostate cancer, HP501 for hyperuricemia, and HP558 for cancer of the esophagus, among others. The firm conducts clinical tests in domestic and overseas areas.
See Also
What is Hinova Pharmaceuticals Inc's Change in Working Capital?
Change in Working Capital
-186.8m
CNY
Based on the financial report for Dec 31, 2024, Hinova Pharmaceuticals Inc's Change in Working Capital amounts to -186.8m CNY.
What is Hinova Pharmaceuticals Inc's Change in Working Capital growth rate?
Change in Working Capital CAGR 5Y
-17%
Over the last year, the Change in Working Capital growth was 32%. The average annual Change in Working Capital growth rates for Hinova Pharmaceuticals Inc have been 7% over the past three years , -17% over the past five years .
